# A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants

> **NCT05653323** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 70 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** VX-993
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05653323
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-14
- **Primary completion:** 2023-09-12
- **Final completion:** 2023-09-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653323, "A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05653323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*